Skip navigation
BelSU DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bsu.edu.ru/handle/123456789/46339
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElagin, V. V.-
dc.contributor.authorBratchikov, O. I.-
dc.contributor.authorZatolokina, M. A.-
dc.date.accessioned2022-04-25T11:18:19Z-
dc.date.available2022-04-25T11:18:19Z-
dc.date.issued2018-
dc.identifier.citationElagin, V.V. Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment / V.V. Elagin, O.I. Bratchikov, M.A. Zatolokina // Research Results in Pharmacology. - 2018. - Vol. 4, № 4.- P. 29-40. - Doi: 10.3897/rrpharmacology.4.31846. - Refer.: p. 39-40.ru
dc.identifier.urihttp://dspace.bsu.edu.ru/handle/123456789/46339-
dc.description.abstractAcute kidney injury (AKI), which is based on ischemic-reperfusion damage, is a widespread life-threatening condition and remains a serious public health problem with a high mortality rate among patients. Pharmacological preconditioning and the use of endothelioprotectors are promising areas in this field, therefore the purpose of this study was to analyze the nephroprotective properties of asialoerythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experimentru
dc.language.isoenru
dc.subjectmedicineru
dc.subjectpharmacologyru
dc.subjectacute kidney injuryru
dc.subjectischemic-reperfusion kidneyru
dc.subjectendothelial dysfunctionru
dc.subjectpharmacological preconditioningru
dc.subjectasialoerythropoietinru
dc.subjectselective inhibitor of arginaseru
dc.titleCorrection of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experimentru
dc.typeArticleru
Appears in Collections:Vol. 4, № 4

Files in This Item:
File Description SizeFormat 
Elagin_Correction.pdf1.99 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.